Summary Ten consecutive patients with Hürthle cell lesions of the thyroid (nodule/adenoma/carcinoma) were studied by 111 In-DTPA-D-Phe 1 -octreotide scintigraphy. Octreotide scintigraphy localized the primary Hürthle cell tumour in eight patients as distinct areas of increased uptake of radionuclide. Two patients with Hürthle cell carcinoma, previously thyroidectomized, had their metastases visualized by octreotide scintigraphy. Northern analyses showed expression of multiple somatostain receptor subtypes. Visualization of the Hürthle cell tumour may be due to a higher expression of somatostatin receptors in the lesions than in surrounding normal thyroid tissue. The tissue/blood 111 In concentration ratios for tumour samples from five patients showed clearly higher values than observed for normal connective tissue, muscle or lymph nodes. A relatively high uptake of 111 In was also observed in goiter tissue, which may lead to misinterpretations. The main indication for octreotide scintigraphy in patients with Hürthle cell carcinoma is suspicion of metastatic disease.
Neuroendocrine tumours, including thyroid tumours such as medullary thyroid carcinoma (MTC), have been shown to express somatostatin receptors (sstr) and can thus be diagnosed by scintigraphic techniques utilizing a radiolabelled somatostatin analogue, 111 In-DTPA-D-Phe 1 -octreotide (Baudin et al, 1996; Tisell et al, 1997) . Five different subtypes of sstr have been cloned and shown to be G-protein coupled receptors with seven transmembrane regions. Sstr2-3 and sstr5 differ from sstr1 and sstr4 regarding amino acid homology and pharmacological profile. Octreotide binds with highest affinity to sstr2 and with lower affinity to sstr3 and sstr5, while somatostatin binds to all subtypes with high affinity (cf. Bruns et al, 1994) . In patients with differentiated thyroid (non-MTC) tumours distant metastases can sometimes be diagnosed and treated with radioiodine. However, one third of these tumours do not accumulate radioiodine (Maxon et al, 1990) . Hürthle (oncocytic) cell lesions (nodule/adenoma/carcinoma) belong to this category. The diagnosis of Hürthle cell lesions is today based upon preoperative cytology, or histopathological examination of surgical specimens, demonstrating oncocytic cell features.
The aims of the present study were to compare the outcome of 111 In-DTPA-D-Phe 1 -octreotide scintigraphy with clinical findings in patients with Hürthle cell lesions of the thyroid and to study the expression of sstr in these lesions by Northern blotting using subtype-specific probes. Furthermore, the 111 In concentrations in tumour or normal tissue (Ti) and blood (B) were determined.
MATERIALS AND METHODS

Patients
During a 3-year period (1995-97) 10 patients (seven women and three men, mean age 68, range 37-86 years) underwent thyroid surgery with subsequent histological demonstration of Hürthle cell lesions. All lesions were reexamined by two pathologists (ON and JM) and classified according to strict criteria (Rosai et al, 1990) as Hürthle cell nodules (n = 2), Hürthle cell adenoma (n = 4) and Hürthle cell carcinoma (n = 4) ( Table 1) . Eight of these patients had palpable thyroid tumours, where preoperative fine needle aspiration indicated Hürthle cell neoplasia (seven patients) or follicular thyroid neoplasia (one patient). Two patients had previously been treated for Hürthle cell carcinoma and had metastatic disease (patient nos V and IX). Patient no. V had local symptoms and underwent palliative resection, while patient no. IX had no further treatment. All patients underwent scintigraphy with 111 Inoctreotide, and eight patients were also investigated by conventional thyroid scintigraphy (cf. below) prior to surgery (Table 1) . 111 In concentrations were determined in both tumour and normal tissues from five patients (Figure 1 ). Tumour biopsies from four patients (I-IV, two adenomas, one nodule and one carcinoma, cf. Table 1) were investigated by Northern analysis and compared with biopsies of histologically normal thyroid tissue from the contralateral lobe of two patients, who underwent hemithyroidectomy for benign adenomas.
Scintigraphy
Ten patients received i.v. 210-230 MBq 111 In-DTPA-D-Phe 1 octreotide (10-20 µg) (Mallinckrodt, The Netherlands). The amount of 111 In bound to octreotide was higher than 98%. Imaging was done 24-48 h after injection of the radiopharmaceutical. A gamma camera (GE 400 AC/T), equipped with a medium energy parallel hole collimator and connected to a GE STARCAM computer system, was used. Data acquisition was done in a dual window setting (173 and 247 keV). Single photon emission computed tomography (SPECT) of the thoracic cage was performed in all patients (cf. Ahlman et al, 1994) . Six patients also underwent thyroid scintigraphy using 99m and the two patients with distant metastases were scanned with Expression of somatostatin receptors in oncocytic (HŸrthle cell) neoplasia of the thyroid 131 I (100 MBq). These two patients with previous thyroidectomy (nos V and IX) were on thyroxin substitution, which was maintained during 111 In-DTPA-D-Phe 1 -octreotide scintigraphy, but discontinued for the radioiodine examination.
Measurement of 111 In concentration in tissue samples and blood
Surgery was performed 5-7 days after injection of 111 In-DTPA-DPhe 1 -octreotide. The surgical specimens from tumour and normal tissues and blood samples, taken during surgery, were weighed and the 111 In concentrations were measured in a calibrated gamma counter equipped with a NaI(T1) well crystal (diameter 7.6 cm, length 7.6 cm, Harshaw, The Netherlands) and a single-channel pulse-height analyser (Elscint, Israel). Corrections were made for background activity and radioactive decay. Tissue-to-blood 111 In concentration ratios (Ti/B), were calculated for biopsied tissues, which were subsequently sent for histopathological examination (cf. Forssell-Aronsson et al, 1995) . Tumour biopsies were included in the analysis, if the biopsy contained more than 80% tumour tissue. Nonthyroid specimens (lymph nodes, muscle, soft tissue and fat) were included, if they were tumour-free and contained less than 20% of adherent tissue.
Northern analyses of sstr 1-5 mRNA expression
Fresh tumour specimens were rapidly frozen in liquid nitrogen. RNA was prepared by acid guanidine thiocyanate-phenol-chloroform extraction. Samples of total RNA (20 µg) were heat-denatured and electrophoresed in a 1% agarose gel with 2.2 mol l -1 formaldehyde, 1 mmol l -1 EDTA, 5 mmol l -1 sodium acetate and 20 mmol l -1 morpholine propane sulphonic acid (pH 7.0) as running buffer. RNA was transferred to positively charged nylon membranes (Boehringer, Mannheim, FRG) using a vacuum transfer system (Hybaid, Middlesex, UK) and crosslinked to the membrane by UV-light (Stratalinker, Stratagene, La Jolla, CA). Membranes were hybridized in rotating flasks at 65°C (Hybaid, Middlesex, UK) using 32 P-labelled antisense RNA probes. The following probes were used: (1) a 1.126 bp PCR fragment of the human sstr1 gene corresponding to nucleotides 352-1478 (Yamada et al, 1992a) ; (2) a 1.7 kb Bam HI/Hind III cDNA fragment of the human sstr2 (Yamada et al, 1992a) ; (3) a 1.9 kb Nco/Hind III cDNA fragment of the human sstr3 (Yamada et al, 1992b) ; (4) a 2.0 kb Nae I/Xbal cDNA fragment of the human sstr4 (Rohrer et al, 1993) ; (5) a 1.6 kb Eco R1/Sal III cDNA fragment of the human sstr5 (Yamada et al, 1993) , and (6) a 982 bp fragment of human G3PDH.
Specific labelling was detected after 3-6 days exposure on an imaging plate, followed by reading in a Phosphor Imager (Molecular Dynamics, Sunnyvale, CA).
RESULTS
Scintigraphy
The six patients subjected to 99m Tc-scintigraphy had thyroid tumours that were cold. In the two patients with previous thyroidectomy no metastases could be identified by 131 I-scintigraphy. 111 In-DTPA-D-Phe 1 -octreotide scintigraphy localized the Hürthle cell lesions as distinct areas of increased uptake of radionuclide in all 10 patients (Figure 2A and B; Table 1 ). In patient no. V with recurrent metastatic disease site localization was obtained by 111 In-DTPA-D-Phe 1 -octreotide in the right low neck region prior to surgery. Multiple lung metastases were also visualized in this patient as well as in patient no. IX ( Figure 2C ).
In concentration in tissue samples
Ti/B ratios of removed Hürthle cell lesions from five patients (Figure 1 ) showed large interindividual variations (range 45-94), but were clearly higher than the Ti/B ratios observed for normal soft tissue, muscle and fat (range 0.8-3.6). Lymph nodes (all without tumour involvement) had values ranging from 1.4 to 12. Normal thyroid tissue had similar values as lymph nodes ( Figure  1 ). Higher levels were observed in parts of the glands with colloid goiter (range 26-35).
Patient no. III with Hürthle cell adenoma underwent total thyroidectomy with lymph node dissection on clinical suspicion of a carcinoma. The histopathological examination demonstrated a Hürthle cell adenoma in a thyroid gland with areas of colloid goiter. The Ti/B ratio of the adenoma was higher (45) than the Ti/B ratios found in the contralateral (26, 32) and pyramidal (34) lobes for all five sstr. The two adenoma patients (nos III and IV) had similar receptor-profiles except for a lack of sstr2. In the controls the normal thyroid tissue selectively lacked sstr2 ( Figure 3 ; Table 2 ).
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British Journal of Cancer (1999) The control tissues showed selective lack of sstr 2. The size of mRNA transcripts is indicated to the right. Membranes were rehybridized with G3PDH to verify the integrity of RNA transferred to the membranes. Table 2 is a schematic summary of the results. Roman numerals refer to patients presented in Table 1 Table 
DISCUSSION
In a previous study of 21 nonmedullary thyroid carcinomas (papillary, follicular and anaplastic tumour types) 111 In-DTPA-D-Phe 1 -octreotide scintigraphy visualized specific uptakes in all patients with primary tumours and in 75% of the metastatic lesions. The examination gave additional information to radioiodine scintigraphy, especially with regard to skeletal metastases. However, radioiodine seemed to be superior in detecting pulmonary metastases (Postema et al, 1996) . To our knowledge, octreotide scintigraphy has not previously been evaluated for Hürthle cell lesions of the thyroid. In this study 10 patients with Hürthle cell lesions were subjected to octreotide scintigraphy. The primary lesions, or distant metastases, were in each case localized as distinct areas of increased 111 In uptake. Eight patients were investigated by other scintigraphic techniques ( 99m Tc; n = 6 and 131 I; n = 2). In six patients subjected to 99m Tc-scintigraphy the thyroid lesion appeared as a cold nodule. In our series two patients with previous thyroidectomy due to Hürthle cell carcinoma had their pulmonary metastases revealed by 111 In-DTPA-D-Phe 1 -octreotide scintigraphy, but not by 131 I scanning. Using double-phase scintigraphy with 99m Tcsestamibi (MIBI) Vattimo et al (1995) reported visualization of primary Hürthle cell tumours. In many centres double-phase MIBI scintigraphy may serve as the first alternative in the evaluation of cold thyroid nodules or metastases. However, octreotide scintigraphy has the advantage that outcome of surgery can be assessed by one single preoperative injection of 111 In-DTPA-D-Phe 1 -octreotide also used for postoperative imaging (Ahlman et al, 1994) . It is important to evaluate the future role of octreotide scintigraphy in patients with Hürthle cell lesions in a prospective study of scintigraphically cold nodules and to investigate whether radiation therapy mediated via sstr can be an alternative in disseminated disease (cf. Wängberg et al, 1997) . One advantage with both octreotide-and MIBI-scintigraphy is that thyroid substitution therapy does not have to be withdrawn before the examinations.
The visualization of Hürthle cell lesions by octreotide scintigraphy is most likely due to a higher number of sstr in the lesions compared with normal thyroid tissue. The receptor-subtype profiles may also influence the visualization, because octreotide has different affinities for the various sstr-subtypes (Bruns et al, 1994) . Very similar receptor profiles were observed in normal thyroid and tumour tissues by Northern blotting, which indicates that octreotide imaging in these thyroid tumours is not due to a change in receptor profile, but rather to an increased number of sstr. A differential diagnostic problem is illustrated by patient no. III with a relatively high uptake of 111 In in nontumour thyroid tissue. The uptake of 111 In in the colloid goiter tissue may represent binding to thyreocytes and lymphocytes. There was no obvious difference between the uptake in Hürthle cells of nodules, adenomas or carcinomas. Uptake of 111 In in the thyroid in benign conditions (endemic colloid goiter, thyroid autonomy and Grave's disease) has been reported previously (Becker et al, 1995) . The relative high uptake of 111 In in colloid goiter tissue may lead to misinterpretations. The main indication for octreotide scintigraphy in patients with Hürthle cell tumour is therefore suspicion of metastatic disease.
